Cardiovascular dysfunction in sepsis and septic shock
Tóm tắt
The optimal therapy for the treatment of sepsis and septic shock remains controversial. Many protocols are followed, using different strategies for initial resuscitation, cardiovascular monitoring, hemodynamic intervention, and eradication of infection. Overall, an aggressive approach to the management of cardiovascular dysfunction in septic shock is warranted. Initially, large volume fluid resuscitation is instituted. Our first choice of resuscitation fluid is 0.9% normal saline. Invasive hemodynamic monitoring using a flotation pulmonary artery catheter as well as invasive arterial blood pressure monitoring is a necessity in the hemodynamic management of septic shock. If the patient remains hypotensive (mean arterial pressure < 65 mm Hg) after adequate volume resuscitation has been established (pulmonary capillary wedge pressure 12 to 15 mm Hg), then vasopressor agents must be instituted. Our first choice is usually dopamine. In patients who remain hypotensive after maximal doses of dopamine are reached, norepinephrine is added. If these agents generate excessive tachycardia or if tachyarrhythmias develop, phenylephrine can be substituted or added. Inotropic agents are useful if the patient demonstrates hypotension with a low cardiac output state. Dobutamine is the agent of choice. We initiate broad-spectrum empiric antibiotics at presentation, modifying the exact regimen based on 1) site of infection; 2) prevailing organisms and antibiotic resistance patterns in the patient’s environment; and 3) other specific risk factors (immunosuppression, chronic disease, exposure and vaccination history, invasive medical devices). When appropriate, aggressive surgical debridement is pursued. Currently, there are no clinical data to support the use of antagonists for sepsis mediators, although various clinical trials remain underway. Steroids are contraindicated except for adrenal replacement therapy.
Tài liệu tham khảo
Kumar A, Parrillo JE: Shock: classification, pathophysiology, and approach to management. In Critical Care Medicine: Principles of Diagnosis and Management. Edited by Bone R, Parrillo JE. St. Louis: Mosby; 1995:291–339. An extensive review of shock physiology and management.
Bone RC, Balk RA, Cerra FB, et al.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 20:1644–1655. A key consensus statement on definitions in sepsis.
Kumar A, Haery C, Parrillo JE: Myocardial dysfunction in septic shock. Crit Care Clin 2000, 16:1–37. A more detailed review on cardiac dysfunction in sepsis and septic shock.
Parker MM, Shelhamer JH, Bacharach SL, et al.: Profound but reversible myocardial depression in patients with septic shock. Ann Int Med 1984, 100:483–490. The original description of human septic myocardial depression.
Cunnion RE, Schaer GL, Parker MM, et al.: The coronary circulation in human septic shock. Circulation 1986, 73:637–644.
Dhainaut JF, Huyghebaert MF, Monsallier JF, et al.: Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987, 75:533–541.
Parrillo JE, Burch C, Shelhamer JH, et al.: A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985, 76:1539–1553. The original description of human myocardial depressant substance.
Kumar A, Thota V, Dee L, et al.: Tumor necrosis factor-alpha and interleukin-1 beta are responsible for depression of in-vitro myocardial cell contractility induced by serum from humans with septic shock. J Exp Med 1996, 183:949–958.
Kumar A, Brar R, Wang P, et al.: The role of nitric oxide and cyclic GMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 1999, 276:R265-R276.
Ognibene F, Parker MM, Natanson C, et al.: Depressed left ventricular performance to volume infusion in patients with sepsis and septic shock. Chest 1988, 93:903–910.
Calvin JE, Driedger AA, Sibbald WJ: An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy. Chest 1981, 80:579–586.
Heinz G, Geppert A, Delle-Karth G, et al.: IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure. Inten Care Med 1999, 25:620–624.
Nasraway SA, Rackow AC, Astiz ME, et al.: Inotropic response to digoxin and dopamine in patients with severe sepsis, cardiac failure, and systemic hypoperfusion. Chest 1989, 95:612–615.
Kreger BE, Craven DE, McCabe WR: Gram-negative bacteremia. IV. Reevaluation of clinical features and treatment in 612 patients. Am J Med 1980, 687:344–355.
Bone RC, Fisher CJ, Clemmer TP, et al.: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987, 317:653–658.